# US 2026/0294869 A1 · Combinations of cancer therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0294869 A1
- Document ID: US20260294869A1
- Status: Published application
- Kind: A1
- Application number: 19/707,946
- Filed: 2026-06-15
- Published: 2026-10-01
- Earliest claimed: 2020-07-09
- Assignees: Merck Patent GmbH
- Applicants: Merck Patent GmbH
- Inventors: Manja Friese-Hamim; Felix Rohdich; Claude Gimmi; Christoph Schultes; Olga Bogatyrova
- Web page: https://patentgrep.com/patent/US20260294869A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/47: Quinolines; Isoquinolines
- A61K 39/001109: {Vascular endothelial growth factor receptors [VEGFR]}
- A61K 39/001135: {Vascular endothelial growth factor [VEGF]}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Combinations of (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide and a VEGFR/VEGF inhibitor, or their physiologically acceptable salts are disclosed. Such combinations are useful for the prophylaxis or treatment of cancer.

## Claims

### Claim 1

A method for prophylaxis or treatment of cancer, the method comprising:
administering to a subject compounds a) and b):
a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof, and
b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3, and VEGF, or a physiologically acceptable salt thereof,
wherein the cancer is glioblastoma.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the inhibitor is bevacizumab.

### Claim 3 (depends on 1)

The method according to claim 1, wherein compounds a) and b) are administered simultaneously.

### Claim 4 (depends on 1)

The method according to claim 1, wherein compounds a) and b) are administered sequentially.
